• NuCana plc operating loss widened to £4.42 million for the three months ended March 31, 2026, while loss attributable to equity holders widened to £3.87 million.
• Research and development expenses climbed to £3.21 million, administrative expenses rose to £1.57 million.
• Net foreign exchange swung to a gain of £363,000, finance income increased to £143,000.
• Cash and cash equivalents declined to £21.53 million at March 31, 2026.
• Board said cash on hand should fund operations for 12 months from issuance of the financial statements, while noting the company has no revenue and does not expect any in the foreseeable future.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NuCana plc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-224224), on May 14, 2026, and is solely responsible for the information contained therein.